Achievement of complete response to nivolumab in a patient with advanced sarcomatoid hepatocellular carcinoma:A case report  

作　　者：Shu-Guang Zhu Hai-Bo Li Ze-Nan Yuan Wei Liu Qing Yang Ying Cheng Wen-Jing Wang Guo-Ying Wang Hua Li 

机构地区：[1]Department of Hepatic Surgery and Liver Transplantation,The Third Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510000,Guangdong Province,China [2]Liver Transplant Branch of Organ Transplant Center,Organ Transplantation Institute of Sun Yat-Sen University,Guangzhou 510000,Guangdong Province,China [3]Guangdong Key Laboratory of Liver Disease Research,The Third Affiliated Hospital of Sun Yat-Sen University,Guangzhou 510000,Guangdong Province,China [4]Department of Medicine,OrigiMed Inc.,Shanghai 201100,China

出　　处：《World Journal of Gastrointestinal Oncology》2020年第10期1209-1215,共7页世界胃肠肿瘤学杂志（英文版）（电子版）

基　　金：The National 13th Five-Year Science and Technology Plan Major Projects of China,No.2017ZX10203205-006-001.

摘　　要：BACKGROUND Sarcomatoid hepatocellular carcinoma(SHC)is a rare subtype of hepatocellular carcinoma(HCC),with a high recurrence rate after surgery.In addition to limited effective treatment for the advanced stage of SHC,the prognosis of patients with this malignancy is worse than that of patients with conventional HCC.CASE SUMMARY We present the case of a 54-year-old man with SHC who underwent radical segmental hepatectomy,which relapsed 4 mo after surgery due to lymphatic metastasis in the porta hepatis.Although a second surgery was performed,new metastasis developed in the mediastinal lymph nodes.Therefore,sorafenib and lenvatinib were sequentially administered as first-and second-line systemic therapies,respectively.However,progressive disease was confirmed based on a recurrent hepatic lesion and new metastatic lesion in the abdominal cavity.Percutaneous transhepatic cholangial drainage was performed to alleviate the biliary obstruction.Because the tumor was strongly positive for programmed death-ligand 1,the patient was started on nivolumab.Imaging studies revealed that after two cycles of immunotherapy,the metastatic lesions decreased to undetectable levels.CONCLUSION The patient experienced continuous complete remission for 8 mo.Immune checkpoint inhibitors are useful for the treatment of advanced SHC.

关 键 词：Sarcomatoid hepatocellular carcinoma Hepatocellular carcinoma Programmed death-ligand 1 IMMUNOTHERAPY Nivolumab Case report 

分 类 号：R735.7[医药卫生—肿瘤]